SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a published independent review of Bladder EpiCheck studies which showed high diagnostic accuracy and high performance for surveillance of disease recurrence in patients with non-muscle invasive bladder cancer (NMIBC).
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click on the link inside the
email and you’re good to go.